Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ofatumumab with CHOP for Richter's Syndrome
NCT01171378Phase 2Completed
- Sponsor
- University of Oxford
- Start
- Apr 2011
- Primary completion
- Feb 2015
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ofatumumab in Richter's syndrome (RS), sponsored by University of Oxford. Primary endpoint: Objective Response Rate at 20 weeks. Started Apr 2011; status: completed.
02
Drugs
ofatumumab
03
Conditions
Richter's syndrome (RS)
Beyond the preview
Go deeper on NCT01171378.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01171378.